SB-657510 NEW
| Price | $45 | $136 | $203 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-23 |
Product Details
| Product Name: SB-657510 | CAS No.: 474960-44-6 |
| Purity: 98.18% | Supply Ability: 10g |
| Release date: 2025/10/23 |
Product Introduction
Bioactivity
| Name | SB-657510 |
| Description | SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting UII-induced inflammatory mediators, such as adhesion molecules, in human vascular endothelial cells and upregulation of cytokines and tissue factors. SB 657510 has a therapeutic effect on diabetes-related atherosclerotic disease in diabetic mouse models. |
| In vitro | The UII-induced increase in adhesion between U937 and EA.hy926 cells was blocked by SB-657510 dramatically. SB-657510 (1 μM; 0.5-8 hours) blocks the expression of tissue factor induced by UII in endothelial cells.[1] SB-706375 (1-10000 nM) inhibits [Ca2+]i mobilization elicited by 10 nM hU-II(IC50 of 180 nM).[2] |
| In vivo | The progression of high-fat diet-induced atherosclerosis and diabetes-associated atherosclerosis inhibited by SB-657510.[1] Levels of phosphorylated ERK are significantly attenuated in the aorta of SB-657510-treated (30 mg/kg/day) diabetic mice (Male Apoe KO mice).[3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 27 mg/mL (53.38 mM), Sonication is recommended. |
| Keywords | urotensin-II (UT) | SB-657510 | SB657510 | SB 657510 | NeurotensinReceptor | Neurotensin Receptor |
| Inhibitors Related | Vincamine | Monomethyl fumarate | Questiomycin A | Pamoic acid disodium | Azathioprine | CRTh2 antagonist 2 | Fezagepras sodium | Benzyl nicotinate | TUG-1375 | CAY10595 | Timapiprant | TUG-424 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Diabetic Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $813.00/50mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-09-25 | |
| $1980.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $1.00/1KG |
VIP6Y
|
Career Henan Chemica Co
|
2020-10-29 | |
| $45.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY